InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,722.26
(
-0.19%
)
US TECH 100
19,517.20
(
0.53%
)
Dow Jones
41,914.75
(
-0.70%
)
Brent Oil
73.04
(
-0.21%
)
Bitcoin
63,332.25
(
0.31%
)
Post# of 54890
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Let's Roll

Send PM Follow Ignore
Followers 883
Posts 304355
Boards Moderated 5
Alias Born 06/09/2006

Let's Roll

Re: None

Thursday, 02/16/2017 9:45:00 AM

Thursday, February 16, 2017 9:45:00 AM

Post# of 54890
$IMLFF InMed Pharmaceuticals has taken a unique low-cost / high-yield approach to developing cannabinoid-based compounds for inclusion in their products. By utilizing the process currently employed to manufacture insulin for diabetes, the company's strategy can scalably produce a wide range of cannabinoids beyond simply THC and CBD. These cannabinoids could have broad-reaching potential, but haven't been studied extensively because they are difficult to extract from the cannabis plant at scale.

https://finance.yahoo.com/news/inmed-pharma-ceo-discusses-companys-140000706.html

Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up